Drug therapy for acquired pendular nystagmus in multiple sclerosis

113Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Acquired pendular nystagmus (APN) is regularly accompanied by oscillopsia and impairment of static visual acuity. Therapeutic approaches to APN remain controversial, and there is no generally accepted therapeutic approach. We tested 14 patients who had suffered from APN caused by multiple sclerosis for several years; 12 patients presented with fixational pendular nystagmus (increasing during fixation) and 2 with spontaneous pendular nystagmus. All 11 patients with fixational pendular nystagmus who were given memantine, a glutamate antagonist, experienced complete cessation of the nystagmus. In contrast, scopolamine caused no (6 of 8) or only a minor (10-50%) reduction of the nystagmus (2 of 8). It was concluded that memantine is a safe treatment option for APN.

Cite

CITATION STYLE

APA

Starck, M., Albrecht, H., Pöllmann, W., Straube, A., & Dieterich, M. (1996). Drug therapy for acquired pendular nystagmus in multiple sclerosis. Journal of Neurology, 244(1), 9–16. https://doi.org/10.1007/pl00007728

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free